Literature DB >> 6411329

Influence of polyamine depletion caused by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on alkylation- and carbamoylation-induced cytotoxicity in 9L rat brain tumor cells in vitro.

S M Oredsson, D F Deen, L J Marton.   

Abstract

Using a colony-forming efficiency assay, we studied the effect of polyamine depletion on the cytotoxicity of four nitrosoureas with different capacities to alkylate and/or carbamoylate biomolecules. 9L rat brain tumor cells were treated with 10 mM alpha-difluoromethylornithine for 48 hr before a 1-hr treatment with nitrosoureas. The cytotoxicity of 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose, which alkylates and subsequently cross-links DNA but does not carbamoylate, was significantly increased by depletion of intracellular polyamines; the dose enhancement ratio of 1.3 is identical to that found for 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl-1-nitrosourea in previous studies. Addition of exogenous putrescine to polyamine-depleted 9L cells 24 hr before treatment prevented this phenomenon. In contrast, the cytotoxicity of 1,3-bis(trans-4-hydroxycyclohexyl)-1-nitrosourea, which carbamoylates only, was significantly decreased in polyamine-depleted cells. This compound alone reduced intracellular polyamine levels. Polyamine depletion did not affect the cytotoxicity of the monoalkylating nitrosoureas N-ethyl-N-nitrosourea and N-methyl-N-nitrosourea. Thus, polyamine depletion apparently potentiates the cytotoxicity only of chloroethylnitrosoureas that alkylate and cross-link.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411329

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.

Authors:  J Seidenfeld; K A Komar; M F Naujokas; A L Block
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Polyamines in biology and medicine.

Authors:  G D Luk; S B Baylin
Journal:  West J Med       Date:  1985-01

3.  Effect of polyamine depletion on chromatin structure in U-87 MG human brain tumour cells.

Authors:  H S Basu; M C Sturkenboom; J G Delcros; P P Csokan; J Szollosi; B G Feuerstein; L J Marton
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

Review 4.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

5.  The growth-inhibitory effect of 4-hydroperoxycyclophosphamide against human non-small cell lung carcinoma is enhanced by low-dose difluoromethylornithine.

Authors:  D C Tsai; G D Luk
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Polyamines in clinical disorders.

Authors:  D F Tierney; L J Marton; A D Hacker; N Lowe
Journal:  West J Med       Date:  1985-01

7.  Effects of alpha-difluoromethylornithine on initiation and promotion of urinary bladder carcinogenesis in a heterotopically transplanted rat urinary bladder.

Authors:  K Rinsho; K Uchida; S Samma; R Oyasu
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

8.  Two polyamine analogs (BE-4-4-4 and BE-4-4-4-4) directly affect growth, survival, and cell cycle progression in two human brain tumor cell lines.

Authors:  C J Bergeron; H S Basu; L J Marton; D F Deen; M Pellarin; B G Feuerstein
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Polyamine-DNA Interactions: Possible Site of New Cancer Chemotherapeutic Intervention.

Authors:  L J Marton; B G Feuerstein
Journal:  Pharm Res       Date:  1986-12       Impact factor: 4.200

Review 10.  Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.

Authors:  Victor A Levin; Sandra E Ictech; Kenneth R Hess
Journal:  CNS Oncol       Date:  2018-01-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.